tetano
Editor, Senior Moderator
Vaccine
. 2022 Jan 20;S0264-410X(22)00054-8.
doi: 10.1016/j.vaccine.2022.01.030. Online ahead of print.
An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines
Fei Liu[SUP] 1 [/SUP], Canbin Feng[SUP] 2 [/SUP], Shiqi Xu[SUP] 3 [/SUP], Qiang Wu[SUP] 4 [/SUP], Jian Tang[SUP] 5 [/SUP], Yan Chen[SUP] 2 [/SUP], Ruisheng Xu[SUP] 2 [/SUP], Fuliang Chen[SUP] 6 [/SUP], Ni Gao[SUP] 4 [/SUP], Zhengzheng Xu[SUP] 2 [/SUP], Shihui Gu[SUP] 7 [/SUP], Yang Lan[SUP] 8 [/SUP], Haibo Zhou[SUP] 2 [/SUP], Xinde Hu[SUP] 9 [/SUP], Xiaojing Wang[SUP] 10 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, and AAV-3xRBD) that elicit strong immune responses against the RBD domain of the SARS-CoV-2 S protein. These immunogenic responses have proven long-lived, with near peak levels for at least six months in mice. Notably, the sera immunized with AAV-3xRBD vaccine contains powerful neutralizing antibodies against the SARS-CoV-2 pseudovirus. Further evidence proven that potent specific antibodies could also be elicited in canines after vaccination with AAV-3xRBD vaccine.
Keywords: AAV; Neutralizing antibody; SARS-CoV-2; Vaccine.
. 2022 Jan 20;S0264-410X(22)00054-8.
doi: 10.1016/j.vaccine.2022.01.030. Online ahead of print.
An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines
Fei Liu[SUP] 1 [/SUP], Canbin Feng[SUP] 2 [/SUP], Shiqi Xu[SUP] 3 [/SUP], Qiang Wu[SUP] 4 [/SUP], Jian Tang[SUP] 5 [/SUP], Yan Chen[SUP] 2 [/SUP], Ruisheng Xu[SUP] 2 [/SUP], Fuliang Chen[SUP] 6 [/SUP], Ni Gao[SUP] 4 [/SUP], Zhengzheng Xu[SUP] 2 [/SUP], Shihui Gu[SUP] 7 [/SUP], Yang Lan[SUP] 8 [/SUP], Haibo Zhou[SUP] 2 [/SUP], Xinde Hu[SUP] 9 [/SUP], Xiaojing Wang[SUP] 10 [/SUP]
Affiliations
- PMID: 35094871
- DOI: 10.1016/j.vaccine.2022.01.030
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, and AAV-3xRBD) that elicit strong immune responses against the RBD domain of the SARS-CoV-2 S protein. These immunogenic responses have proven long-lived, with near peak levels for at least six months in mice. Notably, the sera immunized with AAV-3xRBD vaccine contains powerful neutralizing antibodies against the SARS-CoV-2 pseudovirus. Further evidence proven that potent specific antibodies could also be elicited in canines after vaccination with AAV-3xRBD vaccine.
Keywords: AAV; Neutralizing antibody; SARS-CoV-2; Vaccine.